Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.63 USD | +1.22% | -2.73% | -5.29% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.29% | 18.45M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating